Canon Medical Research Europe, a subsidiary of Canon Medical Systems, has won over 155,000 euros in funding for its proposal to develop an artificial intelligence (AI) tool that can recognize, assess, and measure cancer tumors.
The researchers geared their work toward the management of malignant pleural mesothelioma, commonly referred to as asbestos cancer. Their aim is to create an AI evaluation tool that is able to rapidly measure the size of mesothelioma tumors, which grow in a skin-like manner around the lung, according to a release from Scottish innovation center the Data Lab.
Using this information, the AI tool may be able to determine more quickly and accurately whether new cancer drugs are having a useful effect compared with current human reporting methods.
Canon's award came as a result of winning the Cancer Innovation Challenge, a competition aimed at inspiring technological innovations in Scotland for improving cancer treatment. The Scottish government was the primary financial contributor, and the Data Lab organized the award's distribution.
